Literature DB >> 2572207

Antipsychotic drug use in the United States, 1976-1985.

D K Wysowski1, C Baum.   

Abstract

Data from the National Prescription Audit and the National Disease and Therapeutic Index were used to assess trends in outpatient prescriptions for antipsychotic drugs in the United States from 1976 to 1985. Retail pharmacies dispensed 21 million prescriptions for antipsychotic drugs in 1976 and 19 million in 1985. The three leading antipsychotic drugs-thioridazine, haloperidol, and chlorpromazine-constituted 66% to 69% of antipsychotic prescriptions and, along with trifluoperazine, thiothixene, and fluphenazine, accounted for 90% to 91% of all antipsychotic prescriptions throughout the period studied. Thioridazine was the leading medication, with a consistent third of the market share, while the market share for chlorpromazine decreased from 1976 to 1985 and that for haloperidol increased for the same years. Data also indicate that haloperidol is the antipsychotic drug used most frequently in office-based, private medical practice for patients 60 years of age and older, a declining proportion of women are treated with antipsychotic medications, and use of antipsychotic drugs as monotherapy for the primary diagnosis is increasing. We also obtained data on diagnoses associated with antipsychotic drug use.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2572207     DOI: 10.1001/archpsyc.1989.01810100071013

Source DB:  PubMed          Journal:  Arch Gen Psychiatry        ISSN: 0003-990X


  4 in total

1.  Patterns of drug treatment of schizophrenic patients in Estonia, Spain and Sweden.

Authors:  R A Kiivet; A Llerena; M L Dahl; L Rootslane; J Sánchez Vega; T Eklundh; F Sjöqvist
Journal:  Br J Clin Pharmacol       Date:  1995-11       Impact factor: 4.335

Review 2.  Pharmacokinetics of haloperidol: an update.

Authors:  S Kudo; T Ishizaki
Journal:  Clin Pharmacokinet       Date:  1999-12       Impact factor: 6.447

Review 3.  Schizophrenia and psychostimulant abuse: a review and re-analysis of clinical evidence.

Authors:  P A LeDuc; G Mittleman
Journal:  Psychopharmacology (Berl)       Date:  1995-10       Impact factor: 4.530

Review 4.  Chlorpromazine for schizophrenia: a Cochrane systematic review of 50 years of randomised controlled trials.

Authors:  Clive Elliott Adams; John Rathbone; Ben Thornley; Mike Clarke; Jo Borrill; Kristian Wahlbeck; A George Awad
Journal:  BMC Med       Date:  2005-10-17       Impact factor: 8.775

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.